Navigation Links
Omeros Licenses Novel Antifibrinolytic Agents
Date:1/5/2011

logical side effects. Worldwide revenues for Trasylol® (aprotinin), which was permanently withdrawn in 2008 after its use was found to be associated with increased mortality, peaked at $285 million in 2005.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including four from its PharmacoSurgery™ platform, the most advanced of which is in a Phase 3 clinical program, and one from its Addiction program. Omeros may also have the near-term capability, through its GPCR program, to add a large number of new drug targets to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of protein and small-molecule preclinical programs targeting inflammation, bleeding and central nervous system disorders.

Forward-looking Statements

This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release and include Omeros' ability to advance an antifibrinolytic agent rapidly into the clinic and the ability of its agents to provide more effective bleeding control with fewer side effects than other antifibrinolytics. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Announces Positive Clinical Results of OMS201 in Patients Undergoing Ureteroscopy
2. Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update
3. Omeros to Present at the BioCentury NewsMakers Conference
4. Omeros Enrolls First Patient in Phase 2b Clinical Trial Evaluating OMS302 in Patients Undergoing Cataract Surgery
5. Omeros Successfully Unlocks Orphan GPCRs
6. Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders
7. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
8. Omeros Announces National Institute on Drug Abuses Support for Phase 2 Clinical Study in Addiction Program
9. Daniel K. Spiegelman Elected to Board of Directors of Omeros
10. Omeros Corporation to Host Third Quarter 2009 Financial Results Conference Call on November 19
11. Omeros Prices Initial Public Offering of Common Stock at $10.00 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)...  (AHIP Institute Booth 1021) --  Availity , the ... a wide range of information to help health plans ... Health Insurance Plan,s (AHIP,s) 2015 Institute , June 3-5, ... Availity released a special report to AHIP Institute ... opportunities." The report identifies billions of dollars ...
(Date:6/3/2015)... MARLBOROUGH, Mass. , June 3, 2015 ... RXII ), a biotechnology company focused on ... the areas of dermatology and ophthalmology, today announced ... from the United States Patent and Trademark ... platform (sd‑rxRNA®). The patent, titled "RNA Interference ...
(Date:6/3/2015)... 3, 2015  EIP Pharma LLC ( www.eippharma.com ) ... development of VX-745 in Alzheimer,s disease (AD) is underway.  ... potent inhibitor of the alpha isoform of the protein ... "Recent human genetic data demonstrate that inflammation ... symptomatic Alzheimer,s, while the science also indicates the p38 ...
Breaking Medicine Technology:Availity to Share Insights, Tools and Strategies at AHIP 2015 to Enable Health Plans to Achieve Long-term, Sustainable Success in an Evolving Value-based Environment 2Availity to Share Insights, Tools and Strategies at AHIP 2015 to Enable Health Plans to Achieve Long-term, Sustainable Success in an Evolving Value-based Environment 3RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye 2RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye 3RXi Pharmaceuticals Granted Notice of Allowance for Patent Covering Lead Compound, RXI-109, for Use in the Eye 4EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) 2EIP Pharma announces first patient dosing in phase 2 clinical studies of a novel brain-targeted anti-inflammatory drug candidate, VX-745, for the treatment of Alzheimer's disease (AD) 3
... InfuSystem Holdings, Inc. (NYSE MKT: INFU) ("InfuSystem" or ... related services, today announced that it received a letter ... Amex of the "record date" for the 2012 Annual ... the record date for the Company,s 2012 Annual Meeting, ...
... (NASDAQ: ROCM ) is pleased to announce an addition ... of the Magic3 Hydrophilic Intermittent Catheter with Coude Tip ... very latest Magic3 technology. It provides the ... designed curved tip configuration. The Coude tip is ...
Cached Medicine Technology:InfuSystem Holdings, Inc. Receives Letter From NYSE MKT Regarding Timely Notice Of Record Date For 2012 Annual Meeting Of Stockholders 2Rochester Medical Introduces Magic3® Coude Tip Hydrophilic Intermittent Catheter 2
(Date:6/3/2015)... Fourroux Prosthetics, located at 6630 McGinnis Ferry Rd, ... opening with a ribbon cutting ceremony on Wednesday, June ... kind in the area, Fourroux Prosthetics will provide amputee ... use of patented advanced prosthetics CAD/CAM technology. ... states, “Our goal has always been to provide amputees ...
(Date:6/3/2015)... “ Scanalytics ” was featured on ... features the latest and coolest technology products available to ... of NewsWatch, conducted the review and shared with viewers ... in retail stores. , Tracking statistics in business is ... comes to retail this goes a step beyond revenue ...
(Date:6/3/2015)... Consulting Services is excited to announce their achievement in ... April 2006, they have made it a priority to ... every year they have worked diligently in surpassing this ... they are off to a great start already for ... is the Customer Review site veatchconsultingreviews.weebly.com. At this site ...
(Date:6/2/2015)... June 02, 2015 Allred Dental, a dental ... for the months June-September, 2015 along with a $100 off ... limited time only. , “Sometimes wisdom teeth can be impacted, ... jawbone. They can also only partially break through the gum, ... recovery is easier in young people, as they do not ...
(Date:6/2/2015)... (PRWEB) June 02, 2015 Food Lion ... its sixth annual “Thriller on the Griller” events, starting ... and South Carolina locations. Each event will raise funds ... to restoring a sense of self, restoring the family ... our military families. , Through these events, Food ...
Breaking Medicine News(10 mins):Health News:Fourroux Prosthetics Atlanta to Have Grand Opening Gala & Ribbon Cutting Ceremony 2Health News:Technology to Analyze Foot Traffic in Retail Stores was featured on NewsWatch Television 2Health News:Veatch Consulting Services Is Breaking New Ground in Customer Satisfaction 2Health News:Veatch Consulting Services Is Breaking New Ground in Customer Satisfaction 3Health News:$100 Off Coupon for Wisdom Teeth Extractions Offered at Allred Dental 2Health News:Food Lion to Launch “Thriller on the Griller” Events to Benefit Military Families through Hope For The Warriors® 2Health News:Food Lion to Launch “Thriller on the Griller” Events to Benefit Military Families through Hope For The Warriors® 3
... Inc. (OTC Bulletin Board: SGTI) ("Shengtai" or "the ... grade,glucose products in China, today commented on a ... total of 850 billion RMB (USD 123 billion) ... the next three years,the multi-billion health care plan ...
... susceptibility, study says , , THURSDAY, Feb. 5 (HealthDay News) -- ... variant may affect a person,s risk of multiple sclerosis, according ... D deficiency while in the womb and early in life ... Both genetic and environmental factors play a role in MS, ...
... technology and cardiovascular diseaseHOUSTON, Feb. 5 "I salute ... No. 1 killer - cardiovascular diseases, including stroke. ... served as a clinical scientist and flight surgeon, I ... benefit medical and health care fields -- notably through ...
... 5 According to the Better Sleep,Council,s relationship expert ... help improve their relationship by catching extra,winks together in ... they,can,t sleep well side by side. , ... our mind and body, gives us energy,and improves our ...
... ATS Medical, Inc.,(Nasdaq: ATSI ), manufacturer ... announced today that the Australian Therapeutic Goods,Administration (TGA) ... Aortic Bioprosthesis. The Company looks forward to ... care for the Australian market. , ...
... spray when it was launched on the web in 2004. Now Sinus ... more than 5,000 Rite Aid drug stores. , ... Parsippany, NJ (PRWEB) February 5, 2009 ... pepper nasal spray in 2004 with a handful of sales on eBay. By ...
Cached Medicine News:Health News:Shengtai Pharmaceutical, Inc. Comments on China's Recently Approved Health Care Reform Plan 2Health News:Shengtai Pharmaceutical, Inc. Comments on China's Recently Approved Health Care Reform Plan 3Health News:Vitamin D Deficit May Trigger MS Risk Gene 2Health News:Coalition for Space Exploration Salutes American Heart Month 2Health News:Wake Up Your Relationship With a Good Night in Bed This Valentine's Day 2Health News:Wake Up Your Relationship With a Good Night in Bed This Valentine's Day 3Health News:Wake Up Your Relationship With a Good Night in Bed This Valentine's Day 4Health News:ATS Medical Announces Australian Regulatory Approval for ATS 3f Aortic Bioprosthesis 2Health News:ATS Medical Announces Australian Regulatory Approval for ATS 3f Aortic Bioprosthesis 3Health News:Sinus Buster Pepper Nasal Spray Moves Into Rite Aid Drug Stores 2
4 mm x 9 mm tip....
Large. Double-ended. 3 mm pointed end and 5 mm angled end....
4 mm wide tip....
Double-ended. Blunt and semi sharp 5 mm tips. Designated most popular model or size....
Medicine Products: